Tìm kiếm theo: Chủ đề CRISPR

Duyệt theo: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Hoặc nhập chữ cái đầu tiên:  
Hiển thị kết quả tìm kiếm từ 1 đến 4 trong 4 kết quả phù hợp
  • OER000002549.pdf.jpg
  • Industry article


  • Tác giả : Tacca, Luisa Arake de (2023)

  • Bacteriophages encode anti-CRISPR (Acr) proteins that inactivate CRISPR-Cas bacterial8 immune systems, allowing successful invasion, replication, and prophage integration. Acr9 proteins inhibit CRISPR-Cas systems using a wide variety of mechanisms. AcrIIA1 is encoded by10 numerous phages and plasmids, binds specifically to the Cas9 HNH domain, and was the first11 Acr discovered to inhibit SpyCas9. Here we report the observation of AcrIIA1-induced degradation12 ...

  • OER000002708.pdf.jpg
  • Journal article


  • Tác giả : Dhingra, Yukti (2023)

  • Adaptation in CRISPR-Cas systems immunizes bacteria and archaea against mobile genetic 10 elements. In many DNA-targeting systems, the Cas4-Cas1-Cas2 complex is required for selection 11 and processing of DNA segments containing PAM sequences, prior to integration of these 12 “prespacer” substrates as spacers in the CRISPR array. We determined cryo-EM structures of the 13 Cas4-Cas1-Cas2 adaptation complex from the type I-C system that encodes st...

  • OER000000708.pdf.jpg
  • Journal article


  • Tác giả : Athukoralage, Januka S; McQuarrie, Stuart; Grüschow, Sabine (2020)

  • Type III CRISPR systems detect foreign RNA and activate the cyclase domain of the Cas10 subunit, generating cyclic oligoadenylate (cOA) molecules that act as a second messenger to signal infection, activating nucleases that degrade the nucleic acid of both invader and host. This can lead to dormancy or cell death; to avoid this, cells need a way to remove cOA from the cell once a viral infection has been defeated. Enzymes specialised&...

  • OER000002627.pdf.jpg
  • Journal article


  • Tác giả : Sharrar, Allison (2023)

  • Small CRISPR-Cas effectors are key to developing gene editing therapies due to the packaging constraints in viral vectors. While Cas9 and Cas12a CRISPR-Cas effectors have advanced into select clinical applications, their size is prohibitive for efficient delivery of both nuclease and guide RNA in a single viral vector. Type-V Cas12f effectors present a solution given their small size. Here we describe μCas, a novel class of miniature (<490AA) typ...